# Joohyuk Sohn

Source: https://onco.cc/people/sohn-joohyuk/  
OnCo record `sohn-joohyuk` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Joohyuk Sohn is a Yonsei breast oncologist and investigator on the DESTINY-Breast and TROPION trials.

## Summary

Joohyuk Sohn is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in breast cancer. He leads breast medical oncology trials at Yonsei Cancer Center and has been an investigator on the DESTINY-Breast trials of trastuzumab deruxtecan and the TROPION trials of datopotamab deruxtecan, bringing Korean cohorts into HER2-low, TROP2 antibody-drug conjugate and CDK4/6 studies. His publications include work on cMET activation and resistance to EGFR-directed therapy in triple-negative breast cancer, the D-CARE trial of adjuvant denosumab in early breast cancer, and a phase 3 trial of polymeric micelle-formulated paclitaxel in HER2-negative breast cancer. His interests are HER2-low disease and antibody-drug conjugates.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; breast cancer
- Specialisms: Breast cancer; HER2-low; Antibody-drug conjugates

## Sources

- Yonsei Cancer Center: https://sev.severance.healthcare
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [HER2](https://onco.cc/targets/her2/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [Severance Hospital, Yonsei University](https://onco.cc/institutions/severance/)
- journals: [Cancer research and treatment](https://onco.cc/journals/cancer-research-and-treatment/)
- key papers: [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer](https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/), [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/)

---
JSON: https://onco.cc/api/v1/entities/sohn-joohyuk.json